Implementation of ROTEM-guided hemostatic resuscitation and evolution of transfusion practices: a 15-year population-level analysis in a Level I trauma center
A 15-year population-level analysis at a Level I trauma center demonstrates that implementing ROTEM-guided hemostatic resuscitation significantly reduced red blood cell and fresh frozen plasma transfusions while increasing fibrinogen concentrate use, without altering mortality rates among severely injured patients.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a person suffers a severe injury, the body's immediate response is to stop bleeding, but sometimes this system fails. A condition known as trauma-induced coagulopathy occurs when the blood loses its ability to clot effectively, leading to dangerous, uncontrolled bleeding. For decades, doctors treated this by giving patients large amounts of donated blood products, such as red blood cells, plasma, and platelets, often following a standard recipe based on how much blood the patient appeared to have lost. However, this approach has a downside: giving too much of these fluids can dilute the remaining blood, making clotting even harder and increasing the risk of organ failure. In recent years, medical teams have begun using a different strategy called hemostatic resuscitation. Instead of guessing, they use specialized machines to test the blood's clotting ability in real time, allowing them to give only the specific missing ingredients needed to fix the problem. This shift from a one-size-fits-all approach to a targeted, personalized treatment is the focus of a major new study looking at how these changes have played out over time in a real-world hospital setting.
Researchers at a major trauma center in France, part of a network serving the northern Alps, decided to look back at fifteen years of patient care to see how these new methods changed the way they treated severe injuries. They analyzed data from more than 4,200 adults who were admitted directly to the hospital after serious accidents and required intensive care. The team divided this long period into three distinct eras to track the evolution of their practices. The first era, before 2011, relied entirely on clinical judgment and standard lab tests. The second era, from 2011 to 2013, introduced a machine called ROTEM, which acts like a rapid, point-of-care test to measure how well blood clots. The third era, starting in 2014, kept using the ROTEM machine but also added a standard dose of a drug called tranexamic acid to help stop bleeding early on. By comparing these three periods, the researchers could see exactly how the introduction of these tools and drugs altered the flow of blood products and medications to patients.
The results showed a clear and significant shift in how patients were treated. During the periods when the ROTEM machine was used, the hospital saw a substantial drop in the number of patients who needed red blood cells and frozen plasma. Specifically, the use of red blood cells fell by nearly a third after the machine was introduced, and the drop grew even larger once the tranexamic acid was added to the protocol. At the same time, the use of a concentrated clotting protein called fibrinogen concentrate increased dramatically. In the first phase of using the machine, the use of this concentrate rose by half, and in the later phase, it more than doubled. This suggests that doctors were moving away from giving large volumes of general blood products and instead were identifying specific clotting deficiencies and replacing just those missing components. The number of patients requiring massive transfusions, defined as receiving ten or more units of red blood cells in a single day, also fell sharply, dropping from nearly one in five patients in the earliest period to only one in twenty-five in the most recent period.
Despite these major changes in treatment, the study found that the rate of death among patients in the intensive care unit remained steady throughout all three periods. The researchers noted that while the new methods successfully reduced the amount of blood products needed, they did not appear to lower the overall death rate compared to the older methods. This outcome is important because it challenges the idea that simply reducing blood transfusions automatically saves more lives, but it also highlights a different kind of success. By using the ROTEM machine, doctors were able to avoid exposing patients to unnecessary amounts of blood products, which carries its own risks, such as organ damage and immune reactions. The study suggests that the value of this new approach lies in precision: it allows medical teams to spare patients from receiving treatments they do not need while ensuring that those who truly need specific clotting factors receive them quickly and accurately.
The researchers were careful to point out that their findings come from a single hospital and that the changes in practice happened alongside many other improvements in trauma care over the fifteen-year span, such as better pre-hospital emergency services and surgical techniques. Because of this, they could not prove that the ROTEM machine alone caused the reduction in blood product use, but the timing of the changes strongly suggests it was a key factor. The study also noted that the reduction in blood transfusions began even before the ROTEM machine was fully implemented, indicating that the medical community was already moving toward more careful, targeted strategies. Ultimately, this long-term analysis provides a clear picture of how a mature trauma system adapts to new technology, showing that the future of trauma care is likely to be defined by individualized, data-driven decisions rather than broad, empirical rules.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.